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Background: Human immunodeficiency virus-1 (HIV-1) enters the brain by crossing the blood–brain barrier (BBB) as
both free virus and within infected immune cells. Previous work showed that activation of the innate immune
system with lipopolysaccharide (LPS) enhances free virus transport both in vivo and across monolayer monocultures
of brain microvascular endothelial cells (BMECs) in vitro.
Methods: Here, we used monocultures and co-cultures of brain pericytes and brain endothelial cells to examine
the crosstalk between these cell types in mediating the LPS-enhanced permeation of radioactively-labeled HIV-1
(I-HIV) across BMEC monolayers.
Results: We found that brain pericytes when co-cultured with BMEC monolayers magnified the LPS-enhanced
transport of I-HIV without altering transendothelial electrical resistance, indicating that pericytes affected the
transcytotic component of HIV-1 permeation. As LPS crosses the BBB poorly if at all, and since pericytes are on the
abluminal side of the BBB, we postulated that luminal LPS acts indirectly on pericytes through abluminal secretions
from BMECs. Consistent with this, we found that the pattern of secretion of cytokines by pericytes directly exposed
to LPS was different than when the pericytes were exposed to the abluminal fluid from LPS-treated BMEC
monolayers.
Conclusion: These results are evidence for a cellular crosstalk in which LPS acts at the luminal surface of the brain
endothelial cell, inducing abluminal secretions that stimulate pericytes to release substances that enhance the
permeability of the BMEC monolayer to HIV.
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Human immunodeficiency virus-1 (HIV-1) enters the
central nervous system (CNS) where it is relatively
protected from anti-viral drugs [1-3]. Once in the CNS,
HIV-1 has a number of neurotoxic effects that result in
cognitive, hormonal, vascular, and homeostatic deficits
[4-11]. HIV-1 in the CNS may also act as a source for
re-infecting the periphery [12]. For these reasons, it is
important to understand the mechanisms by which
HIV-1 gains entry into the CNS.
HIV-1 must cross the blood–brain barrier (BBB) to
enter the CNS. HIV-1 crosses the BBB both within
infected immune cells by the Trojan horse mechanism
[13,14] and also as free virus [15]. These mechanisms
are not passive but are highly regulated by intracellular
machinery. Crossing within infected immune cells in-
volves a form of diapedesis and is STAT-1 and JNK-
dependent [16,17]. In contrast, free virus entry is a
multi-step transcytotic process [15,18,19] that is JNK-
independent but does depend on p38 mitogen-activated
protein kinase [20] and glycoprotein interactions [21]
with the mannose-6-phosphate receptor [22]. Both of
these mechanisms, diapedesis of infected immune cells
and free virus transcytosis, are enhanced by inflamma-
tion. This is relevant as HIV-1 and its viral proteins
gp120 and TAT can activate the immune system and the
cells that form the BBB [23-25]. It is important
therefore, to further study the mechanisms by which
neuroinflammation can enhance viral permeability across
the BBB.
Lipopolysaccharide (LPS) application offers a useful
model for studying the effects of neuroimmune activa-
tion on HIV-1 transport across the BBB. LPS is derived
from the bacterial cell wall of gram negative bacteria
[26] and is found in the circulation of HIV-1 patients as
a result of gastroenteropathy-related bacterial transloca-
tion [27]. LPS enhances both immune cell [14] and free
virus [20] transport across the BBB. LPS induces cyto-
kine release into the blood and an even more prolonged
immune response within the CNS [28]. LPS has many
effects on the BBB and its cellular components [29],
including altering paracellular and transcytotic perme-
ability, altering brain-to-blood and blood-to-brain trans-
porters [30-35], and inducing cytokine release [36,37],
actions similar to those induced by HIV-1 and its
proteins [38-43]. LPS should also prove useful for study-
ing the cells that influence and modulate the BBB that
together with brain endothelial cells form the neuro-
vascular unit.
The neurovascular unit consists of endothelial cells,
astrocytes, microglia, and other cells which are in con-
stant crosstalk to inform one another of CNS events and
to regulate BBB function [44]. Cytokines and other
immunoactive substances are important messengers inthis crosstalk. The least studied of these cells is the
pericyte [45] that is also the cell in closest proximity to
brain endothelial cells. The pericyte is a pluripotent cell
and lies under the basement membrane surrounding
CNS capillaries [46-48] and is known to be in intimate
crosstalk with other cells of the neurovascular unit such
as the astrocyte [49]. The pericyte is in direct contact
with brain endothelial cells through both peg and socket
joints and gap junctions. Recently, the pericyte has been
shown to take up the HIV-1 virus and to be a site of
viral replication [50].
Here, we examined the influence of pericytes on free
virus transport across monolayers of brain microvascular
endothelial cells (BMEC) and crosstalk between BMEC
and pericytes in two experimental paradigms. First, we
determined whether co-culture of BMEC with pericytes
would alter the ability of free HIV-1 to cross the BMEC
monolayer under both basal and LPS-treated conditions.
Second, we examined the ability of pericytes to secrete
cytokines either constitutively or induced by abluminal
secretions from BMECs exposed to LPS. Together, the
results show that LPS stimulates a crosstalk between
brain endothelial cells and pericytes that enhance per-
meation of HIV-1 across BMEC monolayers.
Methods
Radioactive labeling
HIV-1 (MN) CL4/CEMX174 (T1) prepared and rendered
non-infective by aldrithiol-2 treatment as previously de-
scribed [51,52] was a kind gift of the National Cancer
Institute, NIH. The virus was radioactively labeled by the
chloramine-T method, a method which preserves vial coat
glycoprotein activity [53,54]. Two mCi of 131I-Na (Perkin
Elmer, Boston, MA), 10 μg of chloramine-T (Sigma) and
5.0 μg of the virus were incubated together for 60s. The
radioactively-labeled virus was purified on a column of
Sephadex G-10 (Sigma, St. Louis, MO). Human serum
albumin (5 μg) was labeled by the chloramine-T method
with 1 mCi of 125I-Na (Perkin Elmer) and purified on a G-
10 column.
Primary cultures of BMECs
Primary cultures of MBECS and mouse brain pericytes
were prepared from 8-week-old CD-1 mice. All experi-
ments were approved by the local (VA St Louis) animal use
committee. BMECs were isolated by a modified method of
Szabó et al. [55] and Nakagawa et al. [56]. In brief, the cere-
bral cortices from 8-week-old CD-1 mice were cleaned of
meninges and minced. The homogenate was digested with
collagenase type II (200 U/mL; Invitrogen, Carlsbad, CA)
and DNase I (30 U/mL; Sigma,) in Dulbecco’s modified
Eagle’s medium (DMEM) (Invitrogen) containing 100
units/mL penicillin, 100 μg/mL streptomycin, 50 μg/mL
gentamicin and 2 mM GlutaMAX™-I (Invitrogen) at 37°C
Table 1 Effects of pericytes on transport rates of
HIV-1(I-HIV) and albumin (I-Alb) and on transendothelial
electrical resistance (TEER) in Monolayers of mouse brain
microvascular Endothelial Cells (BMEC)
I-HIV I-Alb TEER
BMEC: no pericytes 11.5 +/− 0.9 (15) 6.2 +/− 0.4 (15) 60 +/− 3 (15)
BMEC: + pericytes 9.0 +/− 0.4 (14)* 6.3 +/− 0.3 (14) 75 +/− 4 (15)*
Means are reported with their means =/- SE (n). I-HIV and I-Alb transport rates
are in cm/min(10-6) and TEER is in Ω x cm2. *Statistically different from
corresponding “no pericyte” group, p<0.05.
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20% bovine serum albumin (BSA)-DMEM (1,000 × g for
20 min) to remove neuron and glial cells. The micro-
vessels obtained in the pellet were further digested
with collagenase/dispase (1 mg/mL; Roche, Mannheim,
Germany) and DNase I (30 U/mL) in DMEM at 37°C for
30 min. Microvessel fragments containing pericytes and
endothelial cells were separated by a 33% continuous
Percoll (Amersham Biosciences, Piscataway, NJ) gradient
centrifugation (1,000 × g for 10 min) collected and washed
in DMEM (1,000 × g for 10 min). To obtain BMECs, the
obtained microvessel fragments were seeded on 60 mm
culture dishes (BD FALCON™, BD Biosciences, Franklin
Lakes, NJ) coated with 0.05 mg/mL fibronectin (Sigma),
0.05 mg/mL collagen I (Sigma) and 0.1 mg/mL collagen
IV (Sigma). They were incubated in DMEM/Nutrient mix-
ture F-12 HAM (DMEM/F-12) (Invitrogen) supplemented
with 20% plasma derived bovine serum (PDS, Animal Tech-
nologies, Tyler, TX), 100 units/mL penicillin, 100 μg/mL
streptomycin, 50 μg/mL gentamicin, 2 mM GlutaMAX™-I
and 1 ng/mL basic fibroblast growth factor (bFGF; Sigma)
at 37°C with a humidified atmosphere of 5% CO2/95% air.
The next day, the BMECs migrated from the isolated ca-
pillaries and started to form a continuous monolayer. To
eliminate contaminating cells (mainly pericytes), BMECs
were treated with 4 μg/mL puromycin (Sigma) for the first
2 days [57]. After 2 days of the treatment, puromycin was
removed from the culture medium. Culture medium was
changed every other day. After 7 days in culture, BMECs
typically reached 80-90% confluence.
Primary cultures of pericytes
Mouse brain pericytes were obtained by a prolonged, 2-
week culture of isolated brain microvessel fragments under
selective culture conditions because brain microvessel
fragments contain pericytes [56,58,59]. Brain microvessel
fragments were isolated as described above for micro-
vessels, and then the obtained fragments were seeded on
uncoated 60 mm culture dishes (BD FALCON™) in
DMEM containing 20% fetal bovine serum (FBS), 100
units/mL penicillin, 100 μg/mL streptomycin, 50 μg/mL
gentamicin, 2 mM GlutaMAX™-I and incubated at 37°C
with a humidified atmosphere of 5% CO2/95% air. The
culture medium was changed twice a week. After 14 days
in culture, pericytes typically reached 80-90% confluence.
Brain pericytes were characterized by positive immuno-
staining for a-smooth muscle actin and negative for von
Willebrand factor and were used at passage 2–3.
Monoculture and co-culture methods
Monocultures of BMEC were used to produce con-
ditioned media and to study I-HIV permeability. Mono-
cultures of pericytes were used in cytokine assays, and
co-cultures of BMECs with pericytes were used in I-HIVpermeability studies (Table 1, Figure 1). BMEC mono-
layers were obtained by seeding BMECs (4 × 104 cells/
well) on the inside of the fibronectin-collagen IV (0.1 and
0.5 mg/mL, respectively)-coated polyester membrane
(0.33 cm2, 0.4 μm pore size) of a TranswellW-Clear insert
(Costar) and cultured in DMEM/F-12 supplemented with
20% PDS, 100 units/mL penicillin, 100 μg/mL strepto-
mycin, 50 μg/mL gentamicin, 2 mM GlutaMAX™-I, 1 ng/
mL bFGF and 500 nM hydrocortisone (Sigma) at 37°C
with a humidified atmosphere of 5% CO2/95% air until
the BMECs reached confluence (3 days). For monocul-
tures of brain pericytes, cells were seeded (4 × 104 cells/
well) into 24-well culture plates (Costar, Corning, NY)
and used after a few days.
Co-culture of BMECs and brain pericytes was as de-
scribed previously [58]; after a few days of pericyte
culture as outlined above, BMECs (4 × 104 cells/well)
were seeded on the inside of the fibronectin-collagen IV
(0.1 and 0.5 mg/mL, respectively)-coated polyester mem-
brane (0.33 cm2, 0.4 mm pore size) of a TranswellW-
Clear insert (Costar) placed in the well of a 24-well cul-
ture plate containing layers of brain pericytes (pericyte
co-culture) and cultured for 3 days. To check the barrier
integrity of BMECs in the BMEC monolayer and pericyte
co-culture systems, transendothelial electrical resistance
(TEER in Ω × cm2) was measured before the experiments
and after an exposure of LPS using an EVOM
voltohmmeter equipped with STX-2 electrode (World
Precision Instruments, Sarasota, FL). The TEER of cell-
free TranswellW-Clear inserts were subtracted from the
obtained values.
Measurement of permeability across BMEC
Lipopolysaccharide from Salmonella typhimurium (LPS;
Sigma) was dissolved in serum-free DMEM/F-12 (DMEM/
F-12 containing 1 ng/ml bFGF and 500 nM hydrocorti-
sone) to concentrations of 10, 50, and 100 μg/ml. To initi-
ate exposure of in vitro BBB models prepared as above to
LPS, the culture medium containing serum in both the
luminal and abluminal chambers was removed and then
serum-free DMEM/F-12 was added to the abluminal
chamber. Immediately, medium containing various con-
centrations of LPS (10, 50, 100 μg/ml) was added to the
BMEC monolayer
Collect culture medium











Figure 1 Schematic diagram of in vitro BBB models and experimental design. BMECs were seeded on the filter of Costar TranswellW inserts
(BMEC monolayer). In pericyte co-culture, brain pericytes were cultured with BMECs using TranswellW insert without direct contact. Following
treatment with LPS (10, 50, and 100 μg/mL) for 4 hr, both in vitro BBB models were used for HIV-1 transport studies. Conditioned media from the
abluminal chamber of BMEC monolayer was collected for cytokine assay.
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12 without LPS was used as the control medium. TEER
was measured at the end of 4 h incubation at 37°C. To ini-
tiate transport experiments, the medium was removed
and BMECs were washed with physiological buffer
containing 1% BSA (141 mM NaCl, 4.0 mM KCl, 2.8 mM
CaCl2, 1.0 mM MgSO4, 1.0 mM NaH2PO4, 10 mM
HEPES, 10 mM D-glucose and 1% BSA, pH 7.4). The
physiological buffer containing 1% BSA was added to the
outside (abluminal chamber; 0.6 mL) of the TranswellW in-
sert and 131I-HIV-1 (3 × 106 cpm/mL) was loaded into
the luminal chamber. Samples were removed from the
abluminal chamber at 15, 30, 60 and 90 min and immedi-
ately replaced with an equal volume of fresh 1% BSA/
physiological buffer. The sampling volume from the
abluminal chamber was 0.5 mL. All samples were mixed
with 30% trichloroacetic acid (TCA; final concentration
15%) and centrifuged at 5,400 × g for 15 min at 4°C. Radio-
activity in the TCA precipitate was determined in a gamma
counter. The permeability coefficient and clearance of
TCA-precipitable 131I-HIV-1 was calculated according tothe method described by Dehouck et al. [60]. Clearance
was expressed as microliters (μL) of radioactive tracer dif-
fusing from the luminal to abluminal (influx) chamber and
was calculated from the initial level of radioactivity in the
loading chamber and final level of radioactivity in the
collecting chamber:
Clearance μLð Þ ¼ C½ C  VC= C½ L;
where [C]L is the initial radioactivity in a μL of loading
chamber (in cpm/μL), CC is the radioactivity in a μL of
collecting chamber (in cpm/μL), and VC is the volume of
collecting chamber (in μL). During a 90-min period of the
experiment, the clearance volume increased linearly with
time. The volume cleared was plotted versus time, and the
slope was estimated by linear regression analysis. The
slope of clearance curves for the BMEC monolayer plus
TranswellW membrane was denoted by PSapp, where PS is
the permeability × surface area product (in μL/min). The
slope of the clearance curve with a TranswellW membrane
without BMECs was denoted by PSmembrane. The real PS
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from 1 / PSapp = 1 / PSmembrane + 1 / PSe. The PSe values
were divided by the surface area of the TranswellW in-
serts (0.33 cm2) to generate the endothelial permeability
coefficient (Pe, in cm/min).
Cytokine detection
To obtain BMEC-conditioned media, the abluminal
chamber of the BMEC monolayer was filled with 600 μL
of serum-free DMEM/F-12. At the same time 100 μL of
serum-free DMEM/F-12 (DMEM/F-12 containing 1 ng/
ml bFGF and 500 nM hydrocortisone) without or with
100 μg/ml LPS was added to the luminal chamber of the
BMEC monolayer as described above. After 4 h of
exposure, the fluid in the abluminal chamber of the
BMEC monolayer (600 μL) was collected as the BMEC
conditioned media, sterilized by passing it through a
0.45 μm filter syringe, and stored at −80°C until use.
Brain pericytes (4 × 104 cells/well) were seeded on the
wells of 24-well culture plate (Costar). We divided the
pericyte cultures into 4 groups: pericytes treated with
(1) BMEC conditioned medium, (2) LPS-treated BMEC-
conditioned medium, (3) serum-free DMEM/F-12 con-
taining no LPS (control), and (4) serum-free DMEM/
F-12 containing LPS (100 μg/mL) where these media are
from above. Pericytes were washed with serum-free
DMEM/F-12, and then exposed to 200 μL of BMEC-
conditioned medium, LPS-treated BMEC conditioned
medium, or serum-free DMEM/F-12 with or without
LPS (100 μg/mL) for 4 hr at 37°C. Culture supernatant
(200 μL) was collected and stored at −80°C until use.
The 22 cytokines [granulocyte colony-stimulating factor
(G-CSF), granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF), interferon gamma (IFN-g), interleukin-1
alpha (IL-1a), IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12
(p70), IL-13, IL-15, IL-17, interferon-inducible protein-10
(IP-10), keratinocyte chemoattractant (KC), monocyte
chemoattractant protein-1 (MCP-1), macrophage inflam-
matory protein-1 alpha (MIP-1a), regulated upon activa-
tion, normal T-cell expressed and secreted (RANTES),
and tumor necrosis factor-alpha (TNF-a)] in the collected
supernatants, BMEC conditioned medium, and LPS-
treated BMEC conditioned medium were measured with
the mouse cytokine/chemokine LincoplexW kit (Linco Re-
search, St. Charles, MO) by following the manufacturer’s
instructions.
Statistical analysis
Values are expressed as means ± SEM. One-way and
two-way analysis of variances (ANOVAs) followed by
Tukey-Kramer’s test were applied to multiple compari-
sons in the permeability study. In the cytokine assay,
one-way ANOVA followed by Tukey-Kramer’s test were
applied to multiple comparisons among the control,BMEC conditioned medium, and LPS-treated BMEC
conditioned medium groups. Student’s t-test was applied
to comparison between the control and LPS groups. The
differences between means were considered to be signifi-
cant when P values were less than 0.05 using Prism 5.0
(GraphPad, San Diego, CA).
Results
Pericytes affect permeability
Table 1 shows that co-culturing with pericytes improved
brain endothelial cell monolayer TEER but had no effect
on albumin permeability. I-HIV crossed the BMEC mono-
layers with or without pericyte co-cultures faster than I-
Alb despite the much larger size of I-HIV. Pericytes
reduced the permeation of I-HIV across the BBB to a
statistically significant degree (t = 2.60, df = 27, p<0.05).
These results show that monolayers with or without
pericytes are more permeable to HIV-1 than the much
smaller albumin, demonstrating that HIV-1 is crossing
BMEC by a process other than leakage. The results also
show that pericytes have differing effects on the three
mechanisms of permeability illustrated in this table: in-
creasing TEER (decreasing paracellular permeability) and
decreasing HIV permeability (adsorptive transcytosis), but
not affecting albumin permeability (macropinocytosis).
LPS affects permeability
Addition of LPS produced a dose-dependent increase in I-
HIV-1 transport across the BMEC monolayer. Results
(Figure 2) were expressed as percent of control in order to
reduce statistical variance and to allow comparison across
treatments and trials. For I-HIV, two-way ANOVA
showed significant effects for culture conditions [with or
without pericytes: F(1,76) = 29.5, p<0.001] and treatment
[LPS concentration: F(3,76) = 27.5, p<0.001] with no effect
for interaction. Tukey’s multiple comparison test showed
that 50 and 100 μg/ml of LPS increased I-HIV transport
across the monolayer in the absence of pericytes and that
10, 50, and 100 μg /ml of LPS increased I-HIV transport
across the monolayer in the presence of pericyte co-
culture. Additionally, any given concentration of LPS
produced a statistically greater transport of HIV-1 in the
monolayers co-cultured with pericytes when compared to
the monocultures (Figure 2 upper panel).
LPS also decreased TEER (Figure 2, lower panel) as
shown by the two-way ANOVA that found effects for
culture conditions [F(1, 76) = 14.8, p<0.001] and LPS
treatment [F(3,76) = 111.5, p<0.001]. However, Tukey’s
multiple comparisons test found no effect of pericytes
on the LPS-induced decrease in TEER.
Effects of cytokine release
To further investigate the mechanism by which
pericytes, LPS, and brain endothelial cells interact, we
Figure 2 Effects of Pericytes on LPS-induced alterations in I-HIV
permeability (Pe) and transendothelial electrical resistance
(TEER). Upper panel: LPS increased I-HIV transport across the
monolayers in comparison to respective controls (*p<0.05;
**p<0.01; ***p<0.001). Pericytes enhanced the effect of any given
dose of LPS on HIV-1 transport (#p<0.05; ##p<0.001). Lower panel:
LPS decreased TEER (***p<0.001) with pericytes producing no
modification of that effect.
Figure 3 Expression of cytokines by pericytes. Constitutive
expression of seven cytokines was found in the control group with
increased expression of these and induction of two others after
addition of LPS. GM-CSF: granulocyte-macrophage colony-stimulating
factor, IL-1α: interleukin-1 alpha, IP-10: interferon-inducible protein-10,
KC: keratinocyte chemoattractant, MCP-1: monocyte chemoattractant
protein-1, RANTES: regulated upon activation, normal T-cell expressed
and secreted.
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brain endothelial cells could induce cytokine release
from pericytes. We determined the ability of pericytes
to release cytokines either constitutively or when
stimulated by LPS. Of 22 cytokines measured, seven
(G-CSF, GM-CSF, IL-1 alpha, IL-6, IP-1-, KC, and
MCP-1) were constitutively released by pericytes and
two others (IL-5 and RANTES) were induced when
pericytes were exposed to LPS for 4 h (Figure 3). LPS
also caused a statistically significant increase in the
release of each of the seven constitutively- released cy-
tokines, p<0.01 (Figure 3).Endothelial-pericyte crosstalk
We then incubated pericytes with culture media obtained
from brain endothelial cells; in some cases, the endothelial
cells had been exposed to LPS. Table 2 shows that four cy-
tokines were detectable in the endothelial cell-conditioned
culture media. Of the nine cytokines released by pericytes
(Figure 3), endothelial culture media only affected the
release of two of them (Figure 4): KC [F(2,14) = 58.8,
p<0.001] and MCP-1 [F(2,14) = 137, p<0.001]. In both
cases, culture media from endothelial cells that had been
exposed to LPS, but not culture media from cells that
were unexposed, produced the increase.
Discussion
We first studied the effects of pericytes on the perme-
ability of brain endothelial cell monolayers. The barrier
function of brain endothelial cells occurs through a low
level of transcytotic mechanisms (macropinocytosis and
fenestrae), and an increase in paracellular mechanisms
(intercellular tight junctions) [61]. To some degree, the
mechanisms that control and alter transcytotic events
are different from those controlling paracellular perme-
ability [62,63]. Electrical resistance measured by TEER
measures channel connections typically ascribed to para-
cellular permeation. Here, TEER was very low, consistent
with little effect on paracellular channel formation. Al-
bumin permeation, however, was also low, indicating
Table 2 Concentrations of cytokines in abluminal culture
media from BMECs exposed or not exposed to luminal LPS
G-CSF IL-1 alpha IP-10 KC
No LPS 171 +/− 6 9.5 +/− 1.4 18.8 +/− 2.9 0
LPS 191 +/− 9 9.0 +/− 1.1 19.6 +/− 5.3 7.8 +/− 0.9
This culture media was subsequently added to cultures of pericytes (Figure 4).
Cytokines as designated in legend to Figure 3. Means +/− SE are shown,
n = 5/cell. Units are pg/ml.
Figure 4 Release of cytokines from pericytes. Effects of culture
media from brain endothelial cells (BMEC-CM) and culture media
from brain endothelial cells exposed to LPS (BMEC- CM LPS-treated)
on release of keratinocyte chemoattractant (KC) or monocyte
chemoattractant protein-1 (MCP-1) from pericytes. ### p<0.001.
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ture fenestrae would produce both a low TEER and high
albumin permeation, so it is likely that fenestrae were
also not present in large numbers in these cells. Co-
culturing pericytes with the brain endothelial cells sig-
nificantly improved TEER, suggesting improved tight
junction function, but did not alter albumin permeation
(Table 1). BMEC-pericyte co-cultures had significantly
reduced permeation of I-HIV. Although the HIV-1 virus
is much larger than the albumin molecule, the rate at
which I-HIV crossed the brain endothelial cell mono-
layer was much faster than that of I-Alb regardless of
whether the endothelial cells were co-cultured with
pericytes. This is consistent with the vesicular process
for HIV-1 transport being independent of nonspecific
vesicular mechanisms such as macropinocytosis.
LPS produced an increase in I-HIV permeation in the
monolayers co-cultured and not co-cultured with pericytes.
LPS also decreased TEER (that is, it increased paracellular
permeability); therefore, this increase in I-HIVcould beme-
diated by transcytotic or paracellular mechanisms. How-
ever, the presence of pericytes magnified the LPS effect on
HIV-1 permeability without affecting TEER. This suggests
that the pericyte-dependent portion of LPS-enhanced I-
HIV permeation is transcytotic rather than paracellular.
The above results show that pericytes facilitate the LPS-
enhanced transport of HIV-1 across brain endothelial
cells. We then investigated some of the mechanisms by
which pericytes could mediate such facilitation. LPS
crosses the in vivo BBB, even the disrupted BBB, poorly if
at all [64]. In vitro, LPS produces different patterns of
cytokine release when added to the luminal versus the
abluminal chamber, consistent with an inability to cross
the in vitro BBB as well [37,65]. We, therefore, postulated
that LPS was likely acting at the luminal surface of the
brain endothelial cell, rather than at the pericytes in the
abluminal chamber, as the first step in a neuroimmune-
based modulation of the crosstalk between pericytes and
brain endothelial cells. More specifically, we postulated
that LPS acts at the luminal surface of the brain endothe-
lial cell to induce release of soluble factors from its
abluminal surface. These soluble factors would then act
on pericytes, inducing them to release soluble factors that
would modulate brain endothelial cell transcytosis of I-
HIV. To test this hypothesis, we examined the release ofcytokines from BMECs and pericytes. It is known that
both endothelial cells and pericytes release cytokines, that
cytokines are important in communication between the
cells of the neurovascular unit, that cytokines enhance
HIV-1 transcytosis, and that LPS can act on one side of
the BBB to affect the release of cytokines from the other
side [37,44,66,67].
We first exposed the luminal surface of BMEC mono-
layers to a short, 4 h exposure to LPS, then collected the
abluminal culture media from these monolayers and
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exposed to LPS was used as a control. We then assessed
the ability of the culture media to release cytokines from
pericytes. We found that culture media from LPS-
exposed brain endothelial cells did indeed increase the
release of two cytokines, KC and MCP-1, from pericytes.
The level of these cytokines was much higher in the
pericyte culture medias (40–140 pg/ml; see Figure 4)
than in the brain endothelial cell culture medias (see
Table 2), thus ruling out contamination as a source of
these results. Likewise, it is unlikely that LPS from the
endothelial cell culture media caused this stimulation as
the LPS was added to the luminal chamber of the endo-
thelial cells, whereas the media exposed to the pericytes
was from the abluminal chamber. Furthermore, LPS
contamination would have been expected to produce the
cytokine profile observed in Figure 3 and not just
increases in KC and MCP-1. Therefore, the most parsi-
monious explanation of our results fits our hypothetical
model: LPS acting at the luminal surface of brain endo-
thelial cells stimulates release of soluble factors from
their abluminal surface which then modulates pericyte
release of immune-active factors.
The levels of release of KC and MCP-1 are substantial.
Given that the pericyte cultures contained about 50 μg of
protein, we estimate MCP-1 and KC concentrations of
960 and 1440 pg/mg protein. This exceeds the levels pro-
duced in brain after in vivo administration of LPS [67].
Although we found the release of two cytokines from
pericytes was specifically affected, it is likely that the re-
lease of many other immune active substances is similarly
modulated. However, pericyte-secreted MCP-1 could be
directly involved in the enhanced transcytosis of HIV-1.
MCP-1 derived from astrocytes [68] and microglia [69]
mediates cross talk with brain endothelial cells that in-
creases the diapedesis across the BBB of HIV-1 infected
macrophages and monocytes. MCP-1 also affects voltage-
gated potassium channels in brain endothelial cells [70].
Here, the evidence shows that pericytes are also a source
of MCP-1 which is released in response to signals from
brain endothelial cells. It could be that MCP-1 released
from pericytes alters brain endothelial transcytotic pro-
cesses that affect the permeation of free HIV-1.Conclusion
Pericytes potentiate the LPS-enhanced transport of HIV-1
across BMECs. This pericyte potentiation does not affect
TEER and so is likely mediated through transcytotic
mechanisms. We conclude that LPS acts at the luminal
surface of the BMEC monolayer, inducing abluminal se-
cretion of cytokines and other substances that in turn act
on pericytes, the pericytes then secrete factors that en-
hance I-HIV transcytosis across the BMECs.Competing interests
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